BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 24, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Livzon’s COVID-19 vaccine as a booster shot shows efficacy against omicron variant

Feb. 18, 2022
By Doris Yu
Livzon Pharmaceutical Group Inc.’s key interim data from the phase III trials of its recombinant SARS-CoV-2 fusion protein vaccine, V-01, has shown efficacy against the omicron variant. The phase III trial aims to evaluate the efficacy, safety and immunogenicity of V-01 as a booster in adults older than 18 after they have received two doses of inactivated vaccines.
Read More

US FDA targets remdesivir with product-specific guidance

Feb. 18, 2022
By Mari Serebrov
As part of its ongoing effort to speed drug pricing competition in the U.S. through the development of generics, the FDA is releasing another batch of draft and revised draft product-specific guidances on the design of bioequivalence studies to support abbreviated new drug applications. Among the 30 new draft guidances is one specific to remdesivir, which was approved in October 2020 as a COVID-19 treatment.
Read More

Regulatory actions for Feb. 18, 2022

Feb. 18, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amylyx, AN2, Astrazeneca, Beigene, BMS, Cstone, Epygenix, Immune-Onc, Kato, Lupin, Moderna, Poxel, Sanofi, Valbiotis, Zai Lab.
Read More

In the clinic for Feb. 18, 2022

Feb. 18, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aimmune, Alkermes, Arrowhead, Celsion, Edesa, Enanta, Evelo, Gilead, Gracell, Innovent, Kahr, Marker, Maze, Modra, Pharmazz, Poseida, Regencell, Resverlogix, Veru, XNK.


Read More
US-white-house-president.png

White House seeks info on sustainment of COVID testing capacity

Feb. 17, 2022
By Mark McCarty
The Biden administration has posted a request for information (RFI) about the conditions necessary for the in vitro diagnostic industry to sustain testing capacity for communicable disease outbreaks, although the letter commits to no specific actions. The Advanced Medical Technology Association responded to the RFI with the recommendation that the administration quickly commit to the provision of resources as a means of ensuring that “market volatility will no longer determine test availability.”
Read More

Regulatory actions for Feb. 17, 2022

Feb. 17, 2022
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bonalive, Evoendo, Novacyt, Oncimmune.
Read More
Francis Collins, director, U.S. NIH

Collins temporarily assigned new scientific role in US government

Feb. 17, 2022
By Mari Serebrov
As the Biden administration continues to play musical chairs with key U.S. federal health leadership positions, its latest move is naming Francis Collins to serve as science adviser to the president and co-chair of the President’s Council of Advisers on Science and Technology.
Read More

Regulatory actions for Feb. 17, 2022

Feb. 17, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acadia, Avenue, Biontech, Celcuity, GBT, Hemogenyx, Hillstream, Jixing, Lexeo, Mirati, Moderna, Pfizer, Revive, Sirnaomics, Swanbio.
Read More

Other news to note for Feb. 17, 2022

Feb. 17, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Applied DNA Sciences, Aridis, Biontech, Catalyst, Davita Clinical Research, Enveric, Evvivax, Insilico Medicine, Intervivo Solutions, Johnson & Johnson, Mediwound, Mindset, Neopharm, Neumora, Partner, Pfizer, Quoin, Repertoire, Shanghai Fosun, Yumanity.
Read More

Other news to note for Feb. 16, 2022

Feb. 16, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bioniz, Biontech, Biovaxys Technology, Cambrian, Endoceutics, Equillium, Gilead, GMSA, Helsinn, Hookipa, Horizon, Mydecine Innovations, Nova Mentis, Novelty Nobility, Novartis, Recbio, Shionogi, Skye, Telix, Tetra, Theramex, Trestle, Valenzabio, Verity.
Read More
Previous 1 2 … 131 132 133 134 135 136 137 138 139 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of Alzheimer's disease in the brain

    ADPD 2026: Three inflection points to target Alzheimer’s disease

    BioWorld Science
    A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
  • Art concept for Parkinson's disease

    Emerging therapeutic strategies for Parkinson’s at ADPD 2026

    BioWorld
    Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 24, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing